Aurora Cannabis Inc vs AMETEK, Inc. — how do they compare? Aurora Cannabis Inc trades at $3.42 (market cap $178.92M), while AMETEK, Inc. trades at $255.78 (market cap $57.98B). The key difference: AMETEK, Inc. is far larger — about 324.1× Aurora Cannabis Inc's market cap, and AMETEK, Inc. pays a 0.54% dividend while Aurora Cannabis Inc pays none. Which is the better fit depends on your goals.
| ACB | AME | |
|---|---|---|
Market Cap | $178.92M | $57.98B |
Sector | Health | Industrials |
52-Week High | $6.23 | $254.76 |
52-Week Low | $2.58 | $179.28 |
Enterprise Value | $123.48M | $59.52B |
Dividend Yield | — | 0.54% |
Signals from Pluang's Aura AI — not financial advice
Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.
ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.
AME trades at $253.66, up 0.91% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats (Q2 2026 EPS of $2.09 vs. $1.99 expected), revenue growth to $7.40B in 2025, and robust profitability (20.04% net margin). Recent news highlights momentum in 3D printing and electronics testing sectors. Analyst consensus is strongly bullish with a $281.86 price target.
Outlook remains positive given earnings momentum and raised guidance, but risks include elevated valuation (P/E 37.08) and RSI overbought signals. Institutional support is strong with no sell ratings. The stock offers growth potential but requires monitoring of valuation metrics amid current levels near resistance.
Trailing returns across standard periods
Latest headlines on both assets
Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.
Read more on ACB →Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →